It is another year of earnings season, and many companies have continued to fall as scheduled, and the reason for this is nothing more than the bad financial report data, which has lowered the expectations of shareholders, including Longjin Pharmaceutical, which has exploded because of the concept of "industrial **".
On Thursday, Longjin Pharmaceutical Co., Ltd. was again a word board down limit, and there were 240,000 hand sealed orders to close the fall limit, according to the latest price of 646 yuan calculation, about 1600 million yuan. Since January 30, Longjin Pharmaceutical has fallen for 3 consecutive trading days. Since 2024, Longjin Pharmaceutical has accumulated **354%。
or be put on delisting alert
The reason why Longjin Pharmaceutical has continued to fall in the past three trading days should be said to be related to the company's continued loss performance forecast disclosed a few days ago and the possible implementation of delisting risk warning. On the evening of January 29, the 2023 performance forecast disclosed by Longjin Pharmaceutical showed that the company is expected to lose 63 million yuan to 82 million yuan in 2023, compared with 5611 in 2022The loss of 650,000 yuan widened by 688350,000 yuan-2588350,000 yuan. In addition, the company's operating income in 2023 is expected to be 81 million yuan to 99 million yuan. 
On the same night, Longjin Pharmaceutical also disclosed a suggestive announcement that it may be subject to a delisting risk warning, because the net profit in 2023 will be negative and the operating income will be less than 100 million yuan. 
The fryer in the stock bar
As the possession of 5The ** of 640,000 shareholders, in the Longjin Pharmaceutical Stock Bar, many shareholders were also stunned. Some shareholders are asking how much ** space is there below; There are also shareholders who are asking when they can go away after the 3 fall limits; There are also shareholders who bluntly said that according to the current decline method, the stock price will go **.
It has been speculated by the market many times
When it comes to Longjin Pharmaceutical, many shareholders must be familiar with it, after all, it has been hyped by the market many times before as a "well-known bull". For example, at the beginning of 2019, catalyzed by the concept of industrial **, Longjin Pharmaceutical soared from more than 5 yuan at the end of January to more than 23 yuan in mid-April, and the stock price rose by more than 340% in more than 2 months.
Then, from the end of 2021 to the beginning of 2022, Longjin Pharmaceutical ushered in a sharp rise in traditional Chinese medicine** (at that time, it was mainly stimulated by the centralized procurement of traditional Chinese medicine, the announcement of price increases by many traditional Chinese medicine companies, and the encouragement policies of traditional Chinese medicine). Since the daily limit on December 22, 2021, Longjin Pharmaceutical first won 10 consecutive boards, and then the stock price once rose above 24 yuan. At that time, in less than a month, Longjin Pharmaceutical soared by more than 230%. 
Abnormal fluctuation announcements were issued
As the stock price continued to fall sharply, after trading on February 1, Longjin Pharmaceutical issued an announcement on abnormal fluctuations in trading. According to the announcement, in addition to the company's possible delisting risk warning, the company's information disclosure does not violate fair information disclosure, and there is no information that should be disclosed but has not been disclosed.
Moreover, after inquiring in writing with the controlling shareholder and actual controller of the Company, there are no material matters that should be disclosed but have not been disclosed about the Company, nor are there any major matters in the planning stage; At the same time, there is no situation of buying and selling companies during abnormal trading fluctuations. 
25 shares are collectively delisted on alert.
In fact, like the above-mentioned Longjin Pharmaceutical, there are not a few companies whose stock prices have plummeted because the company may be subject to delisting risk warning.
On the one hand, many companies have continued to fall after issuing a risk warning that may be delisted. For example, Holitech, which recently issued an announcement, ushered in 2 one-word board drop limits after the announcement. Aonong Biotech also ushered in 2 one-word board drop limits after the announcement was issued. On the other hand, the stock prices of the ** companies that have recently issued delisting risk warning announcements have fallen heavily after the announcement. For example, Jiayu shares, Hanma Technology, Qingdao Zhongcheng, and Weidi shares have fallen by more than 30% after the announcement; ST Youkeshu, Longjin Pharmaceutical, Jingfeng Pharmaceutical, Xinning Logistics, and Hengyu Information Communication fell by more than 20%. According to the data of Oriental Wealth Choice, since the risk warning announcement that Weidi shares may be subject to delisting risk warning on the evening of January 12, at least 25 shares have issued delisting risk warning announcements in about half a month. The chart below shows the details of these 25 shares:
Many investors said that the number of mandatory delistings** in 2023 will reach a record 43, and the number of delistings** is expected to increase in the future under the new delisting rules. Tian Lihui, dean of the Financial Development Research Institute of Nankai University, said recently that under the new delisting regulations, the delisting mechanism is more standardized and strict, the efficiency of delisting has been improved, and inferior companies can withdraw from the market in a timely manner. And this is undoubtedly the sword of Damocles for the "problem stocks".
It is for investors' information only and does not constitute investment advice
Article**: Oriental Wealth Research Center).